CL2023002922A1 - Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3. - Google Patents

Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3.

Info

Publication number
CL2023002922A1
CL2023002922A1 CL2023002922A CL2023002922A CL2023002922A1 CL 2023002922 A1 CL2023002922 A1 CL 2023002922A1 CL 2023002922 A CL2023002922 A CL 2023002922A CL 2023002922 A CL2023002922 A CL 2023002922A CL 2023002922 A1 CL2023002922 A1 CL 2023002922A1
Authority
CL
Chile
Prior art keywords
muc16
antibodies
formulations containing
human
stabilized formulations
Prior art date
Application number
CL2023002922A
Other languages
English (en)
Inventor
Douglas Kamen
Teng-Chieh Yang
Xiaobin Xu
Haibo Qui
Kenneth Graham
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CL2023002922A1 publication Critical patent/CL2023002922A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona formulaciones farmacéuticas líquidas estables que comprenden un anticuerpo biespecífico humano que se une específicamente a MUC16 humana y a CD3 humano. En determinadas modalidades, las formulaciones contienen, además del anticuerpo biespecífico, un amortiguador, un surfactante, y un azúcar. Las formulaciones farmacéuticas de la presente invención exhiben un grado sustancial de estabilidad de anticuerpos tras el estrés y el almacenamiento.
CL2023002922A 2021-04-02 2023-09-29 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3. CL2023002922A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163170320P 2021-04-02 2021-04-02
US202263313927P 2022-02-25 2022-02-25

Publications (1)

Publication Number Publication Date
CL2023002922A1 true CL2023002922A1 (es) 2024-03-08

Family

ID=81579790

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002922A CL2023002922A1 (es) 2021-04-02 2023-09-29 Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3.

Country Status (12)

Country Link
US (1) US20220332849A1 (es)
EP (1) EP4313008A1 (es)
JP (1) JP2024513835A (es)
KR (1) KR20230165828A (es)
AU (1) AU2022246687A1 (es)
BR (1) BR112023019096A2 (es)
CA (1) CA3213546A1 (es)
CL (1) CL2023002922A1 (es)
CO (1) CO2023014918A2 (es)
IL (1) IL306042A (es)
TW (1) TW202304507A (es)
WO (1) WO2022212885A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
MY158130A (en) * 2010-10-06 2016-08-30 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor )il-4r) antibodies
WO2016036678A1 (en) * 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
IL265369B2 (en) * 2016-09-23 2024-03-01 Regeneron Pharma Antibodies against (MUCIN 16) MUC16

Also Published As

Publication number Publication date
AU2022246687A9 (en) 2023-10-26
AU2022246687A1 (en) 2023-10-12
TW202304507A (zh) 2023-02-01
JP2024513835A (ja) 2024-03-27
IL306042A (en) 2023-11-01
BR112023019096A2 (pt) 2023-12-05
CA3213546A1 (en) 2022-10-06
KR20230165828A (ko) 2023-12-05
CO2023014918A2 (es) 2023-11-20
US20220332849A1 (en) 2022-10-20
EP4313008A1 (en) 2024-02-07
WO2022212885A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
CO2019011021A2 (es) Formulacion estable de anticuerpos
ECSP12012092A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
AR111773A1 (es) Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración
EA201891749A1 (ru) Биспецифические конструкции антител, вовлекающие т-клетки
EA201991769A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ С НИЗКИМ ПОКАЗАТЕЛЕМ pH, СОДЕРЖАЩАЯ КОНСТРУКЦИИ НА ОСНОВЕ АНТИТЕЛА, ОСУЩЕСТВЛЯЮЩИЕ РЕКРУТИНГ Т-КЛЕТОК
CU20190015A7 (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden
CO2019009034A2 (es) Formulación de anticuerpo monoclonal anti-vrs referencia cruzada a solicitudes relacionadas
PE20050394A1 (es) FORMULACIONES DE ANTICUERPO MONOCLONAL anti-lge ALTAMENTE CONCENTRADO
PE20091327A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
BR112014001712A2 (pt) formulações estabilizadas contendo anticorpos anti-pcsk9
CO2021011648A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33
CO2022008684A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-cd20 x anti-cd3
CO2021016183A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-angptl3
CO2023014918A2 (es) Formulaciones estabilizadas que contienen anticuerpos biespecíficos anti-muc16 x anti-cd3
Kozlov et al. Secular trends in average height and age at menarche of ethnic Russians and Komi-Permyaks of the Permsky Krai, Russia.
AR117607A1 (es) Formulaciones de anticuerpo líquidas de alta concentración
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
CO2023000264A2 (es) Formulaciones de anticuerpo de activina a y métodos para utilizarlas
AR127421A1 (es) Formulaciones farmacéuticas que comprenden anticuerpos anti-tg2.
CU20190104A7 (es) Formulación estable del anticuerpo nimotuzumab
EA202091600A1 (ru) Конструкция на основе биспецифического антитела, направленная на muc17 и cd3
Gomez Molecular Mimetism Phenomenon in Sars Cov 2
EA202091393A1 (ru) Анти-мст1 антитела и их применение